Primer probe group and kit for detecting fusobacterium nucleatum

Through the combination of primer probes and the design of kits, combining fluorescence and quenching groups, PCR reaction reagents are optimized, and the problem of low detection efficiency of Flora nucleus is solved, high sensitivity and specific detection are achieved, and detection efficiency is significantly improved. .

CN118910303APending Publication Date: 2024-11-08AUTOBIO DIAGNOSTICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411315273.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has low detection efficiency for F. nuclei and lacks detection methods with high sensitivity and specificity, resulting in long-term clinical testing and low efficacy.

Method used

Provide a combination of primer probes and kits for detecting Floranus, including upstream primers, downstream primers and probes, combining fluorophores and quenching groups, using PCR reaction reagents and betaine to optimize the reaction system to improve detection sensitivity and specificity.

Benefits of technology

Fast, sensitive and specific detection of F. nucleus is achieved, with the detection sensitivity reaching 500 copies/mL, an amplification height is increased by 50%, and non-specific amplification phenomenon is avoided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure SMS_1
    Figure SMS_1
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to a primer probe group and a kit for detecting fusobacterium nucleatum. The primer probe group and the kit provided by the invention are high in sensitivity, high in specificity and rapid in detection, and the problem that the fusobacterium nucleatum can only be clinically identified by a detection method which is long in time consumption and low in detection efficiency at present is solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a primer probe set and a kit for detecting Fusobacterium nucleatum. Background Art

[0002] Fusobacterium nucleatum (Fn) is a Gram-negative, non-spore-forming anaerobic bacillus belonging to the genus Fusobacterium of the Bacteroidaceae family. Its cells are spindle-shaped, tapering at both ends. They are obligate anaerobic, non-spore-forming, and highly selective. They can decompose amino acids and peptides, with butyrate as their primary metabolite. In vitro culture and staining reveal multiple cells connected end-to-end, resembling threads of varying lengths. It naturally occurs in the oral and gastrointestinal microbiota of healthy individuals, its abundance influenced by environmental factors and increased in smokers. Fn has long been considered a conditional pathogenic bacteria, capable of causing oral and gastrointestinal inflammatory lesions, such as periodontitis and gingivitis. Recent studies have linked Fn to the development and progression of inflammatory bowel disease (IBD), appendicitis, and the development and progression of gastrointestinal cancers and chemotherapy resistance. Fusobacterium nucleatum is highly enriched in the tissues and feces of patients with colorectal cancer and may be a key factor in the development of colorectal cancer. It can even induce chemoresistance to 5-fluorouracil in colorectal cancer. It can also cause a variety of diseases outside the oral cavity, such as pericarditis, brain abscess, and osteomyelitis.

[0003] However, currently used culture media are inefficient and non-selective for Fusobacterium nucleatum cultivation, and there are no reagents for detecting Fusobacterium nucleatum nucleic acid. Clinically, isolation, culture, and biochemical identification are primarily relied upon, but these are time-consuming and have low detection efficiency.

[0004] Therefore, the establishment and improvement of systematic detection methods for Fusobacterium nucleatum is of great significance. Rapid, sensitive, and specific bacterial detection methods are particularly critical. According to WHO standards, an ideal detection method should possess high sensitivity and specificity throughout the entire process, be low-cost, rapid, and portable or easily accessible for batch testing. In recent years, systematic detection methods for common pathogens such as Helicobacter pylori and Mycobacterium tuberculosis have emerged, including morphological examination, isolation, culture, and identification, immunological serum testing, real-time fluorescence PCR, genome sequencing, and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI TOFMS). These methods have been widely used in clinical research and sample testing, providing a rich and accurate basis for clinical decision-making.

[0005] In recent years, the clinical pathogenicity mechanism and molecular action pathway of Fusobacterium nucleatum have been gradually clarified. Systematic in vitro detection method research and engineering product development are needed to provide support and assistance for clinical and basic research. There are currently no products available for the detection of molecular biology fluorescence quantitative PCR method, and systematic and engineering research is urgently needed. Summary of the Invention

[0006] In view of this, the present invention provides a primer-probe combination and a kit for detecting Fusobacterium nucleatum, which has high sensitivity, high specificity and rapid detection, and solves the problem that Fusobacterium nucleatum can only rely on isolation, culture and biochemical identification, which are time-consuming and have low detection efficiency in clinical practice.

[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0008] The present invention provides a primer-probe set, comprising an upstream primer, a downstream primer and a probe;

[0009] The upstream primer has:

[0010] (1) the nucleotide sequence shown in SEQ ID NO: 1; or

[0011] (2) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (1), and having the same or similar function as (1); or

[0012] (3) A nucleotide sequence that is at least 95% homologous to the nucleotide sequence shown in (1) or (2);

[0013] The downstream primer has:

[0014] (4) the nucleotide sequence shown in SEQ ID NO: 2; or

[0015] (5) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (4), and having the same or similar function as (4); or

[0016] (6) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (4) or (5);

[0017] The probe has:

[0018] (7) the nucleotide sequence shown in SEQ ID NO: 3; or

[0019] (8) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (7), and having the same or similar function as (7); or

[0020] (9) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (7) or (8);

[0021] The plurality is 2 to 3.

[0022] In some specific embodiments of the present invention, the probes in the primer probe set are connected to a fluorescent group and a quenching group;

[0023] The fluorescent group includes FAM, HEX, ROX, CY5, CY3, CY5.5 or CY7;

[0024] The quenching group includes BHQ1, BHQ2 or BHQ3.

[0025] In some specific embodiments of the present invention, the fluorescent group of the probe in the primer probe set is FAM, and the quencher group is BHQ1.

[0026] In some specific embodiments of the present invention, the primer probe set includes a primer probe set for amplifying and detecting an internal standard gene, and the internal standard gene includes any one of β-globin, GADPH, 18S RNA gene, and RNase P.

[0027] In some specific embodiments of the present invention, the internal standard gene in the primer probe set is β-globin, and the internal standard primer probe set includes an internal standard upstream primer, an internal standard downstream primer, and an internal standard probe;

[0028] The internal standard upstream primer has:

[0029] (10), the nucleotide sequence shown in SEQ ID NO: 10; or

[0030] (11) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (10), and having the same or similar function as (10); or

[0031] (12) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (10) or (11);

[0032] The internal standard downstream primer has:

[0033] (13), the nucleotide sequence shown in SEQ ID NO: 11; or

[0034] (14) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (13), and having the same or similar function as (13); or

[0035] (15) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (13) or (14);

[0036] The internal standard probe has:

[0037] (16), the nucleotide sequence shown in SEQ ID NO: 12; or

[0038] (17) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (16), and having the same or similar function as (16); or

[0039] (18) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (16) or (17);

[0040] The plurality is 2 to 3.

[0041] In some specific embodiments of the present invention, the probes in the primer probe set for amplifying and detecting the internal standard gene are connected to a fluorescent group and a quencher group, and the fluorescent group includes FAM, HEX, ROX, CY5, CY3, CY5.5 or CY7;

[0042] The quenching group includes BHQ1, BHQ2 or BHQ3;

[0043] The fluorescent group of the internal standard gene probe is different from the fluorescent group of the Fusobacterium nucleatum probe.

[0044] In some specific embodiments of the present invention, the fluorescent group of the probe in the primer probe set for amplifying and detecting the internal standard gene is ROX, and the quenching group is BHQ2.

[0045] In some specific embodiments of the present invention, the use of the above primer probe set in detecting Fusobacterium nucleatum;

[0046] The detection is for non-diagnostic purposes.

[0047] In some specific embodiments of the present invention, the primer probe set is used in the preparation of a reagent or kit for detecting Fusobacterium nucleatum.

[0048] The present invention also provides a reagent comprising the above primer probe set.

[0049] The present invention also provides a kit comprising the above primer probe set or the above reagent.

[0050] In some specific embodiments of the present invention, the above-mentioned kit further comprises PCR reaction reagents, wherein the PCR reaction reagents include dNTP, DNA polymerase, buffer, and enzyme activator;

[0051] The buffer comprises one or more of Tricine, KOAc, DMSO, Tween20, glycerol, and betaine.

[0052] In some embodiments of the present invention, the enzyme is a bifunctional DNA polymerase.

[0053] In some specific embodiments of the present invention, the above-mentioned PCR reaction reagents further include UDG enzyme.

[0054] The present invention also provides a detection method, which is based on the above primer probe set detection.

[0055] In some specific embodiments of the present invention, the above detection method is based on the above primer probe set detection.

[0056] In some specific embodiments of the present invention, the above detection method is based on the above reagent detection.

[0057] In some specific embodiments of the present invention, the above detection method is based on the above kit detection.

[0058] In some specific embodiments of the present invention, the reaction system of the above detection method includes: 2-6 μL of 1 mol / L Tricine, 0.5-3 μL of 80% Glycerine, 0.5-2 μL of 10 mol / L KOAc, 0.05-0.5 μL of 10% Tween20, 0.1-0.5 μL of 10% NaN3, 1-5 μL of DMSO, 0.1-1 μL of 100 μmol / L primer probe, 0.1-0.5 μL of 1 U / μL UDG, 1-5 μL of 5 U / μL Tth enzyme, 0.5-3 μL of 20 mmol / L dNTP, and 22-9 μL of 25 mmol / L Mn(OAc).

[0059] The primer probe and kit of the present invention can specifically identify Fusobacterium nucleatum, and its detection sensitivity is high, with a detection sensitivity of 500 copies / mL for Fusobacterium nucleatum. The high specificity is achieved by using a more efficient quenching modification on the probe and a specially optimized PCR reaction reagent. The PCR reaction reagent is added with a PCR enhancer betaine. Betaine is an alkaloid, and the amount added to the PCR reaction reagent is between 0.01% and 1% by mass: (1) betaine can increase the hydration of guanine and cytosine in the guanine- and cytosine-rich region in the minor groove of DNA, affect the structure of DNA molecules, change the flexibility of DNA, and help DNA polymerase extend along the DNA template; (2) betaine can eliminate the dependence of denaturation temperature on bases. The concentration-dependent reduction of the Tm of the high GC content sequence and the close proximity of the Tm of the two PCR primers ultimately reduce the DNA Tm value. Experiments show that after adding betaine, the amplification height and sensitivity are both 1 to 2 Ct earlier than the control group, and the amplification height is about 50% higher. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for describing the embodiments or the prior art.

[0061] Figure 1 Shows the amplification results of three sets of primer probes;

[0062] Figure 2 Shows the nonspecific validation results of the primer-probe combination. DETAILED DESCRIPTION

[0063] The present invention discloses a primer-probe combination and a kit for detecting Fusobacterium nucleatum. Those skilled in the art can refer to the contents of this article and appropriately improve the process parameters to achieve the desired results. It should be noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments. It is obvious that relevant personnel can modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0064] Unless otherwise specified, the raw materials, reagents, consumables and instruments involved in the present invention are all common commercial products and can be purchased from the market.

[0065] The present invention will be further described below with reference to the embodiments.

[0066] Example 1

[0067] 1. Instruments and Reagents

[0068] AutoMolec 3000 fully automatic nucleic acid purification and real-time fluorescence PCR analysis system, nucleic acid extraction or purification reagents.

[0069] 2. Nucleic Acid Extraction and Purification

[0070] DNA was extracted according to the instructions of the nucleic acid extraction and purification kit (manufacturer: Zhengzhou Antu Bioengineering Co., Ltd.; registration number: Yuzheng Xiebei 20180037). After extraction, the samples were stored at -80°C for later use.

[0071] 3. Design of detection primers and probes

[0072] Different pairs of primer probes were designed for Fusobacterium nucleatum according to the NCBI database, and primer probes were designed for human β-globin as shown in Table 1.

[0073] Table 1: Primer probe sequences

[0074]

[0075] 4. Verification of primer-probe combination specificity

[0076] DNA extracted from Fusobacterium nucleatum strain samples was subjected to quantitative PCR using a fully automated nucleic acid purification and real-time fluorescence PCR analysis system, with positive and negative controls included. The reaction system is shown in Table 2.

[0077] Table 2: Reaction system

[0078]

[0079] The PCR program was as follows: 50°C for 2 min; 95°C for 2 min; 95°C for 10 s, and 60°C for 22 s for a total of 45 cycles.

[0080] Test results such as Figure 1 As shown, the three curves represent three sets of primer probes. Combination 1 is better than combination 2 and combination 3 in detecting amplification height and detection Ct. It can be seen that combination 1 is the best. Therefore, combination 1 is selected as the primer probe of the kit of the present invention, and subsequent experiments are performed based on combination 1.

[0081] Based on the above results, it can be seen that the primer-probe combination of this kit can normally detect Fusobacterium nucleatum samples, and no non-specific amplification occurs.

[0082] Example 2: Non-specific validation of primer-probe combinations

[0083] To further improve the detection sensitivity and amplification efficiency of this kit, the PCR reagent components of the reaction system were optimized. Specifically, betaine was added to the reaction system and adjusted to an appropriate concentration to increase the kit's sensitivity. The optimized PCR reagents were validated by testing 10 clinical samples identified as negative by sequencing and 5 positive samples. A normal PCR amplification reaction system was used as a control. The reaction systems for the control group are shown in Table 3, and the reaction systems for the experimental group are shown in Table 4.

[0084] Table 3: Control group reaction system

[0085]

[0086] Table 4: Experimental group reaction system

[0087]

[0088] Table 5: Test results

[0089]

[0090] Figure 2 The test results in Table 5 show that the control group also showed varying degrees of non-specific amplification in the 5 positive samples tested, and the target detection Ct value was significantly later than that of the experimental group. The experimental group did not show non-specific amplification and the detection Ct value was earlier.

[0091] Example 3: Establishment of positive judgment value of the kit

[0092] The ROC curve method is used to determine the positive judgment value for each target in this kit. This method calculates a range of sensitivities and specificities by setting multiple cutoff values ​​for continuous variables. A curve is then plotted with sensitivity as the ordinate and (1-specificity) as the abscissa. The larger the area under the curve, the higher the diagnostic accuracy. This method assumes different sensitivity and specificity values ​​for the test, and the point with the optimal sensitivity and specificity is used as the positive judgment value. The test results of this kit are expressed as Ct values. Determining the positive judgment value for a target is equivalent to determining the Ct value with the optimal sensitivity and specificity.

[0093] The specific test results are shown in Table 6.

[0094] Table 6: Interpretation of test results

[0095]

[0096] The final positive judgment value of Fusobacterium nucleatum determined by this kit is 40, and the positive judgment value of the internal standard is 35.

[0097] Example 4: Determination of kit detection limit

[0098] Five different concentrations of Fusobacterium nucleatum strains were selected, and 20 replicate tests were performed for each concentration sample. The detection rate of each concentration was calculated, and the test results are shown in Tables 7 and 8.

[0099] Table 7: Confirmation of detection limits of Fusobacterium nucleatum strains

[0100] Table 8: Detection Limit Assessment

[0101]

[0102] The above test results show that the detection sensitivity (LOD) of this kit for detecting Fusobacterium nucleatum is 500 copies / mL.

[0103] Example 5: Pathogen Cross-Reaction Verification

[0104] The cross-pathogens detected using this kit are shown in Table 9.

[0105] Table 9

[0106]

[0107] The test results are shown in Table 10.

[0108] Table 10: Cross-pathogen detection results

[0109]

[0110] The above test results show that this kit has no cross reaction with samples such as Salmonella typhimurium, Kloszek, Enterobacter cloacae, Klebsiella pneumoniae, Staphylococcus saprophyticus, Staphylococcus epidermidis, Listeria monocytogenes, Salmonella enteritidis, Staphylococcus aureus, Escherichia coli, human herpes virus, group B Streptococcus, hepatitis C virus, Chlamydia trachomatis, Neisseria gonorrhoeae, Ureaplasma urealyticum, Mycoplasma pneumoniae, adenovirus, hepatitis B virus, and Chlamydia boca.

[0111] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. Primer probe set, including upstream primer, downstream primer and probe; The upstream primer has: (1) the nucleotide sequence as shown in SEQ ID NO: 1; or (2) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (1), and having the same or similar function as (1); or (3) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (1) or (2); The downstream primer has: (4) the nucleotide sequence shown in SEQ ID NO: 2; or (5) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (4), and having the same or similar function as (4); or (6) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (4) or (5); The probe has: (7) the nucleotide sequence shown in SEQ ID NO: 3; or (8) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (7), and having the same or similar function as (7); or (9) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (7) or (8); The plurality is 2 to 3.

2. The primer probe set according to claim 1, characterized in that: The probe is connected to a fluorescent group and a quenching group, and the fluorescent group includes FAM, HEX, ROX, CY5, CY3, CY5.5 or CY7; The quenching group includes BHQ1, BHQ2 or BHQ3.

3. The primer probe set according to claim 1, characterized in that: The invention comprises a primer probe set for amplifying and detecting an internal standard gene, wherein the internal standard gene comprises any one of a beta globin gene, a 18S RNA gene, GADPH and RNase P.

4. The primer probe set according to claim 3, characterized in that: The probes in the primer probe set for amplifying and detecting the internal standard gene are connected to a fluorescent group and a quenching group, and the fluorescent group includes FAM, HEX, ROX, CY5, CY3, CY5.5 or CY7; The quenching group includes BHQ1, BHQ2 or BHQ3.

5. Use of the primer probe set according to any one of claims 1 to 4 in detecting Fusobacterium nucleatum; The detection is for non-diagnostic purposes.

6. Use of the primer probe set according to any one of claims 1 to 4 in preparing a reagent or a kit for detecting Fusobacterium nucleatum.

7. A reagent, characterized in that Comprising the primer probe set according to any one of claims 1 to 4.

8. A kit, characterized in that include: (I) A primer-probe set according to any one of claims 1 to 4; or (II) The reagent as described in claim 7.

9. The kit according to claim 8, characterized in that Also included are PCR reaction reagents, which include dNTPs, DNA polymerase, buffer, and enzyme activator; The buffer comprises one or more of Tricine, KOAc, DMSO, Tween20, glycerol and betaine.

10. A detection method for non-diagnostic purposes, characterized in that: Based on any of the following tests: (i) The primer probe set according to any one of claims 1 to 4; (ii) the reagent according to claim 7; (iii) The kit according to claim 8 or 9.